COVID-19 Innovation Timeline
The development of COVID-19 vaccines and treatments is a story of science, ingenuity and hard work. It is also a story of widespread collaboration and investment powering tenacious R&D.
Discover
Fighting for what counts: Leveraging the power of collaboration to end HIV, tuberculosis, and malaria
Aligned with the Global Fund replenishment, this report captures industry’s contribution to advance progress in the fight against HIV, TB, and malaria.
Read More
The biopharmaceutical industry's COVID-19 lessons learned
This report identifies 10 insights the biopharmaceutical industry has gathered so far as the world moves into the third year of the COVID-19 pandemic. We present them as hard-learned lessons to date – and as urgent strategies to end this pandemic and better prepare for the next one.
Download the report
#VaccinesForLife
Together we can give vaccines the greatest chance to make an even greater impact on our health, our communities, and our world. Discover our new global digital campaign #VaccinesForLife and join us on #TeamVaccines
Learn More
COVID-19 SOLUTIONS
Find out how the biopharmaceutical industry is using the power of innovation and science to tackle COVID-19 from all angles.
#AlwaysInnovating
The African Medicines Agency
AMA has the unique opportunity to become one of the most efficient and modern regulatory systems in the world.
Read More
IFPMA Code of Practice eLearning
Our Code of Practice has evolved over time and it promotes a culture grounded on values, principles and decisions based on good judgement. You can take our new eLearning here!
Start training hereIFPMA in Brief
IFPMA represents the research-based pharmaceutical companies and associations across the globe. The research-based pharmaceutical industry’s 2 million employees research, develop and provide medicines and vaccines that improve the life of patients worldwide. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community find solutions that improve global health.
Tackling Global health challenges
The research-based biopharmaceutical industry is proud to be playing its part in the quest to find effective and sustainable solutions to today’s most pressing health concerns.
Read More
Boosting Innovation and Access
The research-based biopharmaceutical industry is thinking creatively about its innovation and business models to meet new challenges, and is working in collaboration with different players from the scientific community.
Read More
Strengthening Regulatory Systems
Patients everywhere should be treated with high quality medicines and vaccines. Science-based guidelines provide direction for the development, manufacture, and supply of medicines.
Read More
Ethics and Business Integrity
The healthcare community and the public must be confident that research-based biopharmaceutical industry and their employees, wherever they operate, communicate and act in an ethical and professional manner.
Read More
Inventing Medicines and Vaccines
Never have people lived longer and never have so many children been saved from dying in the first years of life. Medicines and vaccines extend and improve the quality of life for many people.
Read More
Our Resources
Influenza vaccination during the COVID-19 pandemic
Read More
Why is flu vaccination so important during the COVID-19 pandemic?
IFPMA_HPP_Why is flu vaccination so important during the COVID-19 pandemic_Infographic
Read More
Three priorities to urgently increase access to COVID-19 vaccines
Innovative biopharmaceutical companies are at the forefront of the global effort to develop and manufacture safe and effective COVID-19 vaccines and treatments. Today, over 12 billion doses of vaccines have been produced, and more than 60 percent of the world’s population have received at least one dose.[1] Getting as many...
Read More
Greg Perry - IFPMA Moderated Panels @Pre-ICDRA 2018
Read More
IFPMA EFPIA PhRMA BIO ABPI Statement - Global COVID-19 Summit: Ending the Pandemic and Building Back Better
Innovative biopharmaceutical companies are at the forefront of the response to the pandemic; not least by developing and manufacturing COVID-19 vaccines in record time. Our industry joins today’s global summit to demonstrate our commitment towards working with governments and global health partners to align on a common vision to expand...
Read More
Join IFPMA
Our membership has three levels tailored to meet specific needs. Full Members have to be R&D-based pharmaceutical companies or national associations whose membership includes innovative pharmaceutical companies; Associate Members of R&D-based pharmaceutical companies and national associations whose permanent staff numbers are less than five, and Affiliate Members that are organizations, associations, companies and institutions who are supportive of the R&D-based
LEARN MOREOur Blog
Is an extension of the TRIPS waiver needed for COVID-19 tools?
Evidence shows that progress made in sharing IP through voluntary agreements, combined with tiered-pricing and not-for-profit arrangements for low- and middle-income countries has led to production of COVID-19 therapeutics exceeding demand for all disease severity levels and in all patient settings. Efforts must now focus on ensuring these products reach those in need. Last week, we saw yet another powerful example of the spirit of...
Read More
Innovative partnership model to improve access to cancer care in LMICs
This blog was originally published on Health Awareness on 3 October 2022. Through public and private sector partnerships, a global initiative innovates for better access to cancer care worldwide. The global prevalence of cancer is increasing rapidly, presenting an especially heavy burden for people in low and middle-income countries (LMICs). Collaborative and innovative thinking is now needed to expand access to quality cancer care. In...
Read More
The biopharmaceutical industry continues to innovate and push science forward to manage the COVID-19 pandemic and be better prepared for future global health threats
Viruses don’t stand still. And neither do we. It’s been almost two years since the administration of the first COVID-19 vaccine in December 2020 and as of September 2022, more than two thirds of people worldwide had received at least one COVID-19 vaccine dose. The biopharmaceutical industry is proud to continue to play a key role in helping to manage the worst global health pandemic...
Read More